Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 16

2229P - Updated safety and efficacy of selpercatinib in patients (pts) with RET-activated thyroid cancer: Data from LIBRETTO-001

Date

21 Oct 2023

Session

Poster session 16

Topics

Tumour Site

Thyroid Cancer

Presenters

Lori Wirth

Citation

Annals of Oncology (2023) 34 (suppl_2): S1145-S1151. 10.1016/S0923-7534(23)01270-X

Authors

L.J. Wirth1, V. Subbiah2, F.P. Worden3, B.J. Solomon4, B. Robinson5, J. Hadoux6, P. Tomasini7, D. Weiler8, B. Deschler-Baier9, D.S.W. Tan10, Y. Lin11, T. Bayt11, P. Maeda11, A. Drilon12, P. Cassier13

Author affiliations

  • 1 Department Of Medicine, MGH - Massachusetts General Hospital, 02114 - Boston/US
  • 2 Department Of Investigational Cancer Therapeutics, Division Of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston/US
  • 3 Internal Medicine, Michigan Medicine University of Michigan, 48109 - Ann Arbor/US
  • 4 Medical Oncology, Peter MacCallum Cancer Center, 8006 - Melbourne/AU
  • 5 Endocrinology, Royal North Shore Hospital, 2065 - Sydney/AU
  • 6 Endocrine Oncology Department, Institut Gustave Roussy, 94805 - Villejuif, Cedex/FR
  • 7 Multidisciplinary Oncology And Therapeutic Innovations, Hôpitaux Universitaires de Marseille Timone, 13005 - Marseille/FR
  • 8 Medical Oncology, Kantonsspital Luzern Switzerland, 6210 - Luzern/CH
  • 9 Comprehensive Cancer Center, UKW - University Hospital Würzburg, 97080 - Würzburg/DE
  • 10 Division Of Medical Oncology, National Cancer Centre Singapore, 168583 - Singapore/SG
  • 11 Lilly Corporate Center, Eli Lilly and Company, 46285 - Indianapolis/US
  • 12 Department Of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, 10065 - New York/US
  • 13 Medical Oncology, Centre Léon Bérard, 69008 - Lyon/FR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 2229P

Background

Selpercatinib, a first-in-class highly selective and potent RET kinase inhibitor with CNS activity, is approved in multiple countries for the treatment of RET-mutant MTC and RET fusion-positive thyroid and lung cancers.

Methods

Updated analysis of selpercatinib in pts with RET fusion-positive thyroid cancer (TC), in LIBRETTO-001 (NCT03157128) was conducted after additional follow up (f/u) of 19 months. Primary endpoint was objective response rate (ORR, RECIST 1.1) by independent review committee (IRC). Secondary endpoints included duration of response (DoR), progression free survival (PFS), and safety.

Results

Efficacy of selpercatinib after RAI (where RAI appropriate) was evaluated in systemic treatment-naïve pts (N=24) and pre-treated pts (N=41) (Table). Naïve and pre-treated pts achieved an ORR of 95.8% and 85.4%, respectively (Table). For pre-treated pts DoR was 26.7 months and PFS was 27.4 months. DoR and PFS data for treatment-naïve pts are still immature approaching and at 2 years, with response ongoing in most pts. At 2 yrs, 95.2% of naïve pts and 57.1% of pre-treated pts remained progression free. In the safety population (N=66), the most common ≥3 grade treatment-emergent adverse events (TEAEs) were: hypertension (15.2%), hyponatraemia (10.6%), diarrhea (7.6%), lymphopenia (7.6%) and increased alanine aminotransferase (6.1%). Two pts (3.0%) discontinued treatment due to TEAEs; 1 pt (1.5%) of these was considered related. Table: 2229P

Treatment naïve (N=24) Prior treatment (N=41)
ORR by IRC, % (95% CI) 95.8% (78.9, 99.9) 85.4% (70.8, 94.4)
Complete response, n (%) 5 (20.8) 5 (12.2)
Partial response, n (%) 18 (75.0) 30 (73.2)
Stable disease, n (%) 1 (4.2) 6 (14.6)
Progressive disease, n (%) 0 (0.0) 0 (0.0)
Not evaluable (NE), n (%) 0 (0.0) 0 (0.0)
PFS by IRC
Median PFS, months (95% CI) NE (44.2, NE) 27.4 (14.5, NE)
Censored, % 21 (87.5) 24 (58.5)
PFS rate at 24 months, % (95% CI) 95.2 (70.7, 99.3) 57.1 (38.6, 71.8)
Median f/u, month 24.9 30.4
DoR by IRC
Median DoR, months (95% CI) NE (42.8, NE) 26.7 (12.1, NE)
Censored, % 21 (91.3) 20 (57.1)
DoR rate at 24 months, % (95% CI) 90.9 (50.8, 98.7) 50.7 (30.4, 67.8)
Median f/u, months 17.8 33.9

NE; Not estimated.

Conclusions

With longer f/u and additional pts, selpercatinib continues to demonstrate very durable responses in pts with RET-fusion thyroid cancer with or without prior therapy, suggesting use of selpercatinib as first systemic therapy appears to be highly effective in treatment of TC. The safety remained tolerable despite longer duration on treatment.

Clinical trial identification

NCT03157128.

Editorial acknowledgement

Legal entity responsible for the study

Eli Lilly and Company.

Funding

Eli Lilly and Company.

Disclosure

L.J. Wirth: Financial Interests, Personal, Advisory Board: Bayer, Coherus, Eli Lilly, Eisai, Exelixis; Financial Interests, Personal, Other, Consultant: Curie Therapeutics, Morphic Therapeutics, Tome Biosciences; Financial Interests, Personal, Other, DMSC: PDS Biotherapeutics; Financial Interests, Institutional, Steering Committee Member: Novartis, Eli Lilly. P. Cassier: Financial Interests, Personal, Advisory Board: Merck Serono/EMD, Roche, Amgen, Boehringer ingelheim; Financial Interests, Personal, Invited Speaker: Amgen; Financial Interests, Personal, Other, Advisor: OSE Immunotherapeutics; Financial Interests, Institutional, Local PI: AbbVie, Blueprint, Exelixis, GSK, Janssen, Novartis, Roche, Taiho, Loxo/Eli Lilly; Financial Interests, Institutional, Coordinating PI: Amgen; Non-Financial Interests, Institutional, Product Samples: Plexxikon, Novartis, MSD, AstraZeneca, GSK. V. Subbiah: Financial Interests, Institutional, Research Funding: Loxo/Eli Lilly. F.P. Worden: Financial Interests, Personal, Advisory Board: Regeneron, Coherus, Merck, EMD, Serono, Eisai, Eli Lilly, Soligenix, Exelixis; Financial Interests, Personal, Advisory Role: Eisai, EMD, Serono; Financial Interests, Personal, Royalties: UpToDate; Financial Interests, Institutional, Research Funding: Kura Oncology, Merck, Regeneron, Adlai Nortye, Eli Lilly, Loxo. B.J. Solomon: Financial Interests, Institutional, Advisory Board: AstraZeneca, Novartis, Merck, Bristol Myers Squibb; Financial Interests, Personal, Invited Speaker: Pfizer, AstraZeneca, Roche/Genentech; Financial Interests, Personal, Advisory Board: Amgen, Roche-Genentech, Eli Lilly, Takeda, Janssen; Financial Interests, Personal, Full or part-time Employment, Employed as a consultant Medical Oncologist at Peter MacCallum Cancer Centre: Peter MacCallum Cancer Centre; Financial Interests, Personal, Member of Board of Directors: Cancer Council of Victoria, Thoracic Oncology Group of Australasia; Financial Interests, Personal, Royalties: UpToDate; Financial Interests, Institutional, Steering Committee Member, Principal Investigator and Steering Committee Chair: Roche/Genentech, Pfizer; Financial Interests, Institutional, Steering Committee Member: Novartis. J. Hadoux: Financial Interests, Personal, Advisory Board: Ipsen, Lilly, Pharma Mar; Financial Interests, Institutional, Invited Speaker: AAA, Pfizer; Financial Interests, Institutional, Advisory Board: Eisai, HRA pharma. D. Weiler: Financial Interests, Personal, Advisory Board, Invited Speaker: Lilly, Roche; Financial Interests, Personal, Advisory Board: MSD, Merck. P. Tomasini: Financial Interests, Personal, Expert Testimony: AZ, Roche, BMS, Takeda, Amgen, JNJ. B.D. Baier: Financial Interests, Personal, Expert Testimony: Eli Lilly. D.S.W. Tan: Financial Interests, Personal, Advisory Board: Amgen, Novartis, Boehringer Ingelheim, C4 Therapeutics, AstraZeneca, GSK, Takeda, Eisai, Guardant, Merck, Pfizer, Roche; Financial Interests, Institutional, Research Grant: AstraZeneca, Amgen, Pfizer, ACM Biolabs; Financial Interests, Personal, Steering Committee Member: Novartis. Y. Lin, T. Bayt: Financial Interests, Personal, Full or part-time Employment: Eli Lilly and Company; Financial Interests, Personal, Stocks or ownership: Eli Lilly and Company. P. Maeda: Financial Interests, Personal, Full or part-time Employment: Eli Lilly and Company; Financial Interests, Personal, Stocks or ownership: Eli Lilly and Company; Financial Interests, Personal, Stocks/Shares: Bayer. A. Drilon: Financial Interests, Personal, Advisory Board: Ignyta/Genentech/Roche, Loxo/Bayer/Lilly, Takeda/Ariad/Millennium, TP Therapeutics, AstraZeneca, Pfizer, Blueprint Medicines, Helsinn, BeiGene, BerGenBio, Hengrui Therapeutics, Exelixis, Tyra Biosciences, Verastem Oncology, MORE Health, AbbVie, 14ner/Elevation Oncology, Remedica Ltd., ArcherDX, Monopteros, Novartis, EMD Serono, Melendi, Liberum, Repare RX, Amgen, Janssen, EcoR1, Monte Rosa; Financial Interests, Personal, Other, CME: Medscape, Onclive, PeerVoice, Physicians Education Resources, Targeted Oncology, Research to Practice, PeerView Institute, Paradigm Medical Communications, WebMD, MJH Life Sciences, Med Learning, Imedex, Answers in CME, Medscape, Clinical Care Options, AiCME; Financial Interests, Personal, Other, CME, Consulting: Axis; Financial Interests, Personal, Other, Consulting: Nuvalent, Merus, mBrace, EPG Health, Harborside Nexus, Ology, TouchIME, Entos, Treeline Bio, Prelude, Applied Pharmaceutical Science, Inc; Financial Interests, Personal, Invited Speaker: Chugai Pharmaceutical, Remedica Ltd, RV More; Financial Interests, Personal, Stocks/Shares: Treeline Biosciences; Financial Interests, Personal, Royalties: Wolters Kluwer; Financial Interests, Personal, Other, stocks: mBrace; Financial Interests, Institutional, Funding, Research Funding: Pfizer, Exelixis, GSK, Teva, Taiho, PharmaMar; Financial Interests, Personal, Funding, Research: Foundation Medicine; Non-Financial Interests, Member: ASCO, AACR, IASLC; Other, Food/Beverage: Merck, PUMA, Merus; Other: Boehringer Ingelheim. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.